Three-year study shows significant and sustained weight reduction with tirzepatide and a markedly lower risk of progression from prediabetes to type 2 diabetes.
Canadian company Sandoz is set to launch the very first generic semaglutide in 2026, making this costly treatment more accessible, possibly raising other issues.